Roche Österreich

What Roche Österreich does

Roche Österreich is the Austrian operating arm of the global Roche Group (F. Hoffmann-La Roche Ltd, Basel, Switzerland), structured as three wholly owned Vienna-registered limited liability entities: Roche Austria GmbH (pharmaceutical wholesale, FN 105679 k), Roche Diagnostics GmbH (FN 165444 a), and Roche Diabetes Care Austria GmbH (FN 426377 a). Together, these entities distribute innovative oncology, antiviral, and central nervous system medications alongside an integrated in-vitro diagnostics portfolio built on the cobas® platform (including Elecsys®, Lightcycler®, cobas Integra®, Benchmark®, TaqMan®, and Septifast®) and the Accu-Chek® consumer diabetes franchise (blood glucose meters, test strips, insulin pumps, CoaguChek®). The company also references FoundationOne® genomic profiling services and pursues gene therapy research using viral vectors and CRISPR-Cas9 technology for neurological, ophthalmological, hemophilia, and oncology applications.

The business operates a B2B, enterprise field-sales model targeting Austrian hospitals, laboratories, pharmacies, and medical professionals, supplemented by inside-sales customer service hotlines (including 24-hour emergency services) for Accu-Chek insulin pump users and CoaguChek customers. Roche Österreich's primary segments are healthcare providers/medical professionals and patients, with patient organizations and self-help groups (approximately 1,700 in Austria) forming a secondary stakeholder segment supported through funding, expertise, and contact networks. Distribution is Austria-only (the website explicitly restricts itself to Austrian residents) and proceeds through direct enterprise sales for pharmaceuticals and diagnostic instruments and pharmacy/reseller channels for diabetes care consumables. The Austrian operations are governed by multiple supervisory authorities including the Magistrat der Stadt Wien, the Bundesministerium für Soziale Sicherheit, and the BASG, with active memberships in WKO, Pharmig, FOPI, IV, ÖDGH, respAct Austria, and PRVA. Revenue is not separately disclosed; the global Roche Group reported CHF 60.9 billion in FY2024 and invested EUR 14 billion in R&D in 2022, of which Austria-specific figures are not publicly broken out.

Leadership as of 2025 comprises Alexander Mülhaupt (General Manager, Roche Austria GmbH, appointed March 2025, with 23 years of Roche experience across the USA, UK, Switzerland, and Canada) and Dr. Uta-Maria Ohndorf (General Manager, Roche Diagnostics GmbH and Roche Diabetes Care Austria GmbH). The entity is recognized as a top employer in Austria's chemistry and pharmaceutical sector (Trend, kununu, Statista).

Name

Roche Österreich

Legal name

Roche Austria GmbH

Website

https://roche.at

Company type

Private

Operating status

Operating

Short description

Roche Österreich is the Austrian subsidiary of the global Roche Group, operating three Vienna-based entities that distribute pharmaceuticals, in-vitro diagnostics (cobas® platform), and diabetes care products (Accu-Chek®) to Austrian hospitals, laboratories, pharmacies, and patients.

Ownership category

akta.pro rank

Product category

Pharmaceuticals and Diagnostics

NAICS

Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413), Biological Product (except Diagnostic) Manufacturing (325414), Surgical and Medical Instrument Manufacturing (339112), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

Keywords

• Pharmaceutical products
• In-vitro diagnostics
• Diabetes management
• Diagnostic systems
• Clinical chemistry

Headquarters

HQ city

Vienna

HQ country

Austria

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Wholesale: Roche Austria GmbH operates in wholesale of pharmaceuticals and related activities. The company develops and distributes innovative medications targeting oncology, viral infections, and central nervous system disorders.
2. Diagnostic Systems and Lab Diagnostics: Roche Diagnostics GmbH develops and produces emergency diagnostics systems, conducts wholesale and retail distribution of laboratory diagnostics and diagnostic systems, provides technical service for these systems, and performs chemical-medical analyses.
3. Diabetes Care Products: Roche Diabetes Care Austria GmbH distributes diabetes care products in Austria, including Accu-Chek portfolio of blood glucose meters and insulin pumps.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels9 records

Core offering

Roche Österreich develops, manufactures, and distributes innovative pharmaceutical products (primarily cancer, viral infection, and CNS disorder treatments) alongside the cobas diagnostic platform for in-vitro diagnostics and the Accu-Chek product line for diabetes management. The company operates through three legal entities—Roche Austria GmbH for pharmaceuticals, Roche Diagnostics GmbH for diagnostic systems, and Roche Diabetes Care Austria GmbH for consumer diabetes products—serving healthcare providers, laboratories, and individual patients across Austria.

Product overview

Roche Österreich operates three distinct legal entities comprising a unified healthcare portfolio. Roche Austria GmbH focuses on pharmaceutical products, including innovative cancer medications, virus infection treatments, and central nervous system disorders. Roche Diagnostics GmbH provides a comprehensive diagnostic systems portfolio centered on the cobas® platform, encompassing laboratory diagnostics, molecular diagnostics, point-of-care testing, tissue diagnostics, and diabetes care solutions. Roche Diabetes Care Austria GmbH specializes in diabetes management through the Accu-Chek® brand, offering blood glucose meters, insulin pumps, and associated consumables. These three entities together cover the full spectrum from pharmaceutical development and manufacturing to diagnostic solutions and patient care management.

Differentiator

Problem solved

Functional benefit

Brands

• Accu-Chek: Roche Diabetes Care brand for blood glucose monitoring systems, insulin pumps, and diabetes management solutions distributed in Austria.
• Roche Diagnostics
• FoundationOne
• CoaguChek

Products and services

• cobas diagnostic platform Automated diagnostic platform for laboratories and hospitals performing clinical chemistry, immunoassay, molecular diagnostics, and other in-vitro testing; serves hospital and clinical laboratories, healthcare providers, and medical professionals across Austria.
• Accu-Chek diabetes care products Blood glucose monitoring systems, test strips, insulin pumps, and diabetes management solutions for individuals with diabetes and their caregivers; consumer-facing brand sold through pharmacies in Austria.
• Roche Pharmaceuticals Innovative prescription medications covering cancer treatment (oncology), viral infections, and central nervous system (CNS) disorders; distributed to hospitals, pharmacies, and physicians across Austria.
• CoaguChek coagulation monitoring Point-of-care coagulometer for patient self-testing and professional use in monitoring oral anticoagulation therapy; intended for patients on vitamin K antagonist therapy and healthcare providers managing anticoagulation.
• Accutrend point-of-care testing Portable point-of-care system for measuring blood glucose, cholesterol, and triglycerides outside clinical laboratories; targeted at healthcare professionals and individual users for rapid screening.

Quantifiable outcome

• Roche invested 14 billion EUR in R&D in 2022, demonstrating commitment to medical innovation
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• WKO (Austrian Federal Economic Chamber)coreOthersRoche Austria GmbH is a member of the WKO, the Austrian Federal Economic Chamber, which represents business interests in Austria.
• Pharmig (Austrian Pharmaceutical Industry Association)coreOthersRoche Austria GmbH is a member of Pharmig, adhering to the association's code of conduct for pharmaceutical companies.
• FOPI (Forum of Research-Based Pharmaceutical Industry)coreStrategic or Co-development PartnerRoche Austria is a member of FOPI, the forum representing research-based pharmaceutical companies in Austria, engaging in policy discussions and industry standards.
• respAct Austria (Austrian Business Council for Sustainable Development)minorOthersRoche Austria is a member of respAct Austria, the Austrian Business Council for Sustainable Development, supporting corporate sustainability initiatives.
• PRVA (Public Relations Verband Austria)minorOthersRoche Austria is a member of PRVA, the Austrian Public Relations Association.
• IV (Industrial Association)coreOthersRoche Diagnostics GmbH is a member of IV (Industrial Association), representing industrial interests.
• ÖDGH (Association of Austrian Diagnostics and Diagnostics Device Manufacturers)minorOthersRoche Diagnostics GmbH is a member of ÖDGH, the Austrian association for diagnostics and diagnostics device manufacturers.
• PHAOR AGcoreStrategic or Co-development PartnerPHAOR AG, based in Basel, holds 1% stake in Roche Diagnostics GmbH and Roche Diabetes Care Austria GmbH. Parent company relationship within Roche Group structure.
• Roche Pharmholding B.V.coreStrategic or Co-development PartnerRoche Pharmholding B.V., based in the Netherlands, holds 99% stake in Roche Diagnostics GmbH, representing the primary ownership structure within Roche Group.
• The Valuable 500minorStrategic or Co-development PartnerRoche has committed to The Valuable 500, an organization working to use economic power to drive sustainable change for the 1.3 billion people worldwide with disabilities.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/roche
• YouTubeyoutube.com/playlist?list=PLmXzuVn0p6GB-85psDFtNMZFJQ5MdOZQf
• Facebookfacebook.com/RocheAustria%20
• LinkedInlinkedin.com/company/roche
• Instagraminstagram.com/roche_in_austria

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roche Österreich